What PsyLabs does

PsyLabs is a federally licensed, vertically integrated manufacturer of naturally derived psychedelic active pharmaceutical ingredients (APIs), headquartered in Cape Town, South Africa, with GMP-compliant and ISO 22000-certified cultivation and production facilities located in the mountains of Lesotho. Founded in 2020, the company controls the full value chain from controlled cultivation of Psilocybe cubensis and iboga to pharmaceutical-grade extraction, purification, and stabilization, supported by filed (pending) intellectual property covering extraction methodologies and process optimization aimed at standardization, reproducibility, and potential bioequivalence between botanical extracts and refined APIs.

The company's commercial product portfolio centers on two platforms: NPX-5, a naturally derived psilocybin product offered as 5% w/w bulk powder and 5mg precision capsules (approved by Australia's TGA for use in a Phase IIb clinical trial), and a comprehensive ibogaine platform spanning Ibogaine HCl, Ibogaine Freebase, and Total Alkaloid Extracts in multiple dosage formats. Pipeline compounds include mescaline and DMT under active R&D licenses. PsyLabs exports to Canada, the United Kingdom, Portugal, Slovenia, and Australia, supplying pharmaceutical companies, clinical research organizations, and academic institutions under direct B2B, quote-based, and long-term supply agreements.

The business model is sales-led B2B, generating revenue primarily through one-time and contracted supply of GMP APIs and clinical trial products, supplemented by formulation development and manufacturing collaborations with CDMOs. The company operates as a subsidiary of Psyence BioMed Ltd. (Nasdaq: PBM), which is both the primary investor (with $4M in 2025 follow-on funding) and the dominant customer. A February 2026 share-for-share exchange restructured the relationship so that PsyLabs now owns approximately 49.98% of Psyence BioMed, creating reciprocal cross-ownership rather than a clean parent-subsidiary structure.

Name

PsyLabs

Legal name

PsyLabs

Website

https://psylabs.life

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

PsyLabs is a federally licensed, GMP-compliant manufacturer of naturally derived psychedelic APIs (psilocybin, ibogaine, mescaline, DMT) based in South Africa, supplying pharmaceutical companies, CROs, and academic institutions for clinical research and drug development.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Pharmaceutical-grade psychedelics
• Psychedelic API manufacturing
• GMP-compliant cultivation
• Clinical trial supply
• Active pharmaceutical ingredients

Headquarters

HQ city

Cape Town

HQ country

South Africa

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredient (API) Supply: Supply of pharmaceutical-grade psychedelic APIs including psilocybin and ibogaine to pharmaceutical companies, clinical research organizations, and academic institutions for research and clinical trial purposes. Revenue is generated through product sales under supply agreements and long-term partnership arrangements.
2. Clinical Trial Product Supply: Manufacturing and supply of GMP-compliant psychedelic compounds for clinical trials. Products include NPX-5 psilocybin capsules and ibogaine products for use in regulated clinical research programs.
3. Formulation Development and Manufacturing Partnerships: Collaborative partnerships for formulation development, API supply, and manufacturing collaborations with pharmaceutical companies and CDMOs for commercial development of psychedelic therapeutics.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

PsyLabs is a federally licensed, vertically integrated manufacturer of naturally derived psychedelic active pharmaceutical ingredients (APIs) for research and clinical programs worldwide. Its core offerings include pharmaceutical-grade psilocybin (NPX-5 in bulk powder and 5mg precision capsules) and a GMP-grade ibogaine platform (Ibogaine HCl, Ibogaine Freebase, and Total Alkaloid Extracts), produced at ISO 22000-certified facilities and exported globally for clinical trials and therapeutic development.

Product overview

PsyLabs is a vertically integrated manufacturer of naturally derived psychedelic active pharmaceutical ingredients (APIs) for research and clinical programs. The company operates federally licensed cultivation and GMP-compliant extraction facilities in Southern Africa. Its core product portfolio includes NPX-5 (a pharmaceutical-grade psilocybin product derived from Psilocybe cubensis available as bulk powder and precision capsules) and a comprehensive ibogaine platform (including Ibogaine HCl, Ibogaine Freebase, and Total Alkaloid Extracts in various dosage formats). The pipeline also includes mescaline and DMT compounds under active R&D licenses. PsyLabs exports APIs, botanical extracts, and advanced formulations to clinical research organizations, pharmaceutical companies, and clinical trial sites worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• NPX-5: Psilocybin product derived from controlled cultivation of Psilocybe cubensis, delivered in consistent bulk powder and precision capsule formats. NPX-5 5mg psilocybin capsules have been approved by TGA for Phase 2b clinical trial in Australia.

Products and services

• NPX-5 Psilocybin Pharmaceutical-grade naturally derived psilocybin product from controlled Psilocybe cubensis cultivation, available in bulk powder (5% w/w psilocybin) and precision 5mg capsule formats for clinical research and psychedelic-assisted psychotherapy.
• Ibogaine HCl High-purity crystalline ibogaine hydrochloride powder produced under GMP-compliant manufacturing for precise dosing in clinical research and therapeutic development.
• Ibogaine Freebase Pharmaceutical-grade freebase ibogaine product manufactured under GMP-compliant processes for clinical research and early-stage therapeutic development.
• Total Alkaloid Extracts Full-spectrum iboga alkaloid extracts containing multiple psychoactive compounds, produced under GMP-compliant processes for research applications.
• Clinical Trial Product Supply Manufacturing and supply of GMP-compliant psilocybin (NPX-5) and ibogaine products with regulatory documentation, certificates of analysis and international export support for use in regulated clinical trial programs.

Quantifiable outcome

• Successfully exported psychedelic products to 5 countries including Canada, UK, Portugal, Slovenia, and Australia
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and secondary.

• Southern Star ResearchcoreStrategic or Co-development Partner · 8 April 2026Clinical research organization conducting Psyence BioMed's Phase IIb trial evaluating natural psilocybin (NPX-5) for treating Adjustment Disorder in cancer patients in palliative care using GMP-compliant psilocybin manufactured by PsyLabs.
• Ramsay Health CaresecondaryStrategic or Co-development Partner · 8 April 2026Clinical trial site partner added to expand Australian clinical site network from three to five locations to support Phase IIb trial enrollment and accelerate recruitment.
• NeuroCentrixsecondaryStrategic or Co-development Partner · 8 April 2026Clinical trial site partner added to expand Australian clinical site network from three to five locations to support Phase IIb trial enrollment and improve operational efficiency across study sites.
• CDMOs (Contract Development & Manufacturing Organizations)secondaryStrategic or Co-development PartnerPsyLabs works with CDMOs for EU GMP refinement and scale-up, clinical trial supply, regulatory progression, drug development pathways, and international distribution and export.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Usona Institute: Usona Institute is a non-profit medical research organization sponsoring psilocybin clinical trials and conducting psilocybin API manufacturing. Comparable to PsyLabs as a psilocybin API producer supporting clinical research, though structured as a non-profit.
• Mind Medicine (MindMed): MindMed is a psychedelic drug development company pursuing clinical programs including LSD and MDMA-based therapies. Comparable as a psychedelic drug developer that relies on API supply partners similar to PsyLabs, though MindMed focuses on drug development rather than manufacturing.
• GH Research: GH Research develops mebufotenin (5-MeO-DMT) therapies and has in-house GMP manufacturing capabilities. Comparable as a vertically integrated psychedelic API and drug developer with regulatory-grade production, overlapping with PsyLabs' GMP manufacturing approach.
• Beckley Psytech: Beckley Psytech is a clinical-stage psychedelic drug developer pursuing psilocybin and DMT-based therapies. Comparable as a peer psychedelic drug developer using APIs analogous to those produced by PsyLabs for clinical trials.
• Compass Pathways: Compass Pathways develops psilocybin-based therapeutics (COMP360) and has scaled GMP synthetic psilocybin manufacturing. It is the most advanced psilocybin drug developer and the most direct comparator for PsyLabs on psilocybin API supply, though Compass uses synthetic rather than naturally derived psilocybin.
• Optimi Health: Optimi Health is a Canadian GMP psychedelic API manufacturer producing natural psilocybin and MDMA. Comparable as a direct competitor in natural psychedelic API manufacturing for clinical and research markets.
• Filament Health: Filament Health is a natural psilocybin drug developer and API manufacturer pursuing FDA-approved naturally derived psilocybin drug candidates. It is the closest natural-product peer, competing in the same botanical psilocybin API category as PsyLabs' NPX-5.
• Cybin: Cybin is a clinical-stage psychedelic drug developer with deuterated psilocybin and DMT programs. Comparable as a psychedelic-focused drug developer that competes for clinical trial API supply and partnership arrangements similar to those PsyLabs supports.

Emerging players

• Natural MedTech: Natural MedTech is a Jamaica-based natural psychedelic cultivation and extraction company. Comparable as a peer in naturally derived psychedelic cultivation and extraction, though it operates in a different jurisdiction and serves overlapping research and clinical customers.

Broad incumbents

• ATAI Life Sciences: ATAI Life Sciences is a broad psychedelic and mental health drug development platform holding multiple psychedelic programs. Comparable as a large sponsor of psychedelic drug development that consumes APIs analogous to those manufactured by PsyLabs, though ATAI is a drug developer rather than an API manufacturer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PsyLabs